SA
Sign upLog In
INO

Inovio Pharmaceuticals, Inc. focuses on developing DNA-based immunotherapies and vaccines for infectious diseases and cancer. Its lead product candidates include INO-4800, a COVID-19 vaccine, and VGX-3100, a treatment for cervical dysplasia, which are positioned in competitive markets with significant unmet medical needs.

HealthcareBiotechnologylow - Inovio has high fixed costs associated with R&D and clinical trials, with no current revenue to offset these expenses.

Business Overview

01Product sales from clinical trials (0% as currently no revenue)
02Collaborative agreements with pharmaceutical companies (0% as currently no revenue)
03Grants and funding for research (0% as currently no revenue)

Inovio's business model is primarily based on the development of innovative DNA-based therapies, which it seeks to monetize through partnerships, licensing agreements, and potential future product sales. The company has a competitive advantage in its proprietary platform technology for delivering DNA vaccines, which has shown promise in various clinical trials.

What Moves the Stock

Clinical trial results for INO-4800 and VGX-3100

Partnership announcements with larger pharmaceutical companies

Regulatory approvals from the FDA or other health authorities

Market sentiment regarding the biotechnology sector

Watch on Earnings
Progress in clinical trialsPartnership and collaboration announcementsCash burn rate and funding needs

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption from competing vaccine platforms

Emergence of alternative therapies for COVID-19 and cervical dysplasia

Increased competition from established pharmaceutical companies with more resources

High debt levels relative to market cap and revenue generation

Liquidity risks due to negative cash flow

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - As a biotech firm, Inovio's performance is less directly tied to the economic cycle compared to consumer discretionary sectors.

Interest Rates

Higher interest rates could increase the cost of capital for Inovio, impacting its ability to fund ongoing R&D and clinical trials, which are critical for its growth.

Credit

minimal - The company does not rely heavily on credit for operations, but its high debt/equity ratio indicates potential vulnerability to credit conditions.

Live Conditions
Russell 2000 FuturesDow Jones FuturesS&P 500 Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

high - The stock has shown significant price fluctuations, reflective of the biotech industry's inherent risks.

Key Metrics to Watch
Clinical trial enrollment rates
Cash runway and funding announcements
Partnership developments and licensing agreements
Market reactions to FDA submissions

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.